Pharmacologic interactions of multidrug therapy for dyslipidemia.
Despite the best available medical therapy inclusive of statins, substantial residual risk remains for atherothrombotic cardiovascular disease. Non-statin lipid-lowering therapy may help address this critical unmet need through reduction of the levels of low-density lipoprotein and other atherogenic lipoproteins. In the past few years, several landmark trials have provided important information regarding the efficacy and safety of non-statin therapy for dyslipidemia and cardiovascular risk reduction.
Published In/Presented At
Mehta, N., & deGoma, E. M. (2013). Pharmacologic interactions of multidrug therapy for dyslipidemia. Current atherosclerosis reports, 15(2), 303. https://doi.org/10.1007/s11883-012-0303-7
Medicine and Health Sciences
Department of Medicine, Cardiology Division